rheumatology
Rheumatoid arthritis

IV to SC tocilizumab switch okay for most

Most RA patients who switch from intravenous to subcutaneous tocilizumab are able to maintain disease control but efficacy is reduced in heavier patients, results of a phase III study shows. Patients who weighed below 70 kg maintained remission after switching, while the remission rate fell from 72.7% (8/11) to 27.3% (3/11) in patients above that weight. ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic